Smruthi Organics Ltd
NSE: BSE: 540686
₹112.05
(-1.15%)
Mon, 02 Mar 2026, 04:08 am
Market Cap1.28B
PE Ratio27.95
Dividend1.34
Health Technology
Pharmaceuticals: Major
24.5KSmruthi Organics Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (10.3x coverage).
- Smruthi Organics's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Smruthi Organics's dividend is above the markets top 25% of dividend payers in India (3.08%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
health
- Smruthi Organics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Smruthi Organics is profitable, therefore cash runway is not a concern.
- Smruthi Organics is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (44.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.3x debt.
- Smruthi Organics's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (145.5% vs 65.6% today).
- Interest payments on debt are well covered by earnings (EBIT is 4.4x coverage).
- Smruthi Organics's level of debt (65.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Smruthi Organics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Eaga's compensation has been consistent with company performance over the past year, both up more than 20%.
- Eaga's remuneration is higher than average for companies of similar size in India.
misc
- Smruthi Organics is not covered by any analysts.
- Smruthi Organics has significant price volatility in the past 3 months.
past
- Smruthi Organics's 1-year earnings growth exceeds its 5-year average (792.5% vs 62.5%)
- Smruthi Organics has delivered over 20% year on year earnings growth in the past 5 years.
- Smruthi Organics used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Smruthi Organics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Smruthi Organics's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (792.5% vs 22.7%).
- Smruthi Organics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Smruthi Organics's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Smruthi Organics's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Smruthi Organics is good value based on assets compared to the IN Pharmaceuticals industry average.
- Smruthi Organics is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Smruthi Organics is good value based on earnings compared to the India market.
- BSE:540686 is up 11.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:540686 is up 11.2% outperforming the market in India which returned 8% over the past month.
- 540686 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 540686 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800